75970-64-8

Basic information

• Product Name: 1-(4-fluorobenzyl)-N-piperidin-4-yl-1H-benzimidazol-2-amine dihydrobromide
• Synonyms: 1-(4-fluorobenzyl)-N-piperidin-4-yl-1H-benzimidazol-2-amine dihydrobromide;Norastemizole Hydrobromide;1-[(4-Fluorophenyl)Methyl]-N-4-piperidinyl-1H-benziMidazol-2-aMine HydrobroMide
• CAS NO: 75970-64-8
• Molecular Formula: 2BrH*C₁₉H₂₁FN₄
• Molecular Weight: 486.2191232
• EINECS: 278-353-7
• Product Categories: Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 75970-64-8.mol
• Article Data: 5

Chemical Properties

• Melting Point: 170-178?C
• Boiling Point: 519.8°C at 760 mmHg
• Flash Point: 268.2°C
• Appearance: /
• Vapor Pressure: 6.62E-11mmHg at 25°C
• Storage Temp.: Refrigerator
• Solubility: Methanol (Slightly), Water (Slightly)
• CAS DataBase Reference: 1-(4-fluorobenzyl)-N-piperidin-4-yl-1H-benzimidazol-2-amine dihydrobromide(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-fluorobenzyl)-N-piperidin-4-yl-1H-benzimidazol-2-amine dihydrobromide(75970-64-8)
• EPA Substance Registry System: 1-(4-fluorobenzyl)-N-piperidin-4-yl-1H-benzimidazol-2-amine dihydrobromide(75970-64-8)

Safety Data

• Hazardous Substances Data: 75970-64-8(Hazardous Substances Data)

Usage

Chemical Properties

1-(4-fluorobenzyl)-N-piperidin-4-yl-1H-benzimidazol-2-amine dihydrobromide is Off-White Solid

Uses

1-(4-fluorobenzyl)-N-piperidin-4-yl-1H-benzimidazol-2-amine dihydrobromide is An antihistamine used to treat allergic rhinitis and asthma which does not induce adverse effects such as cardiac arrhythmia, fatigue, or general body weakness.

InChI:InChI=1/C19H21FN4.2BrH/c20-15-7-5-14(6-8-15)13-24-18-4-2-1-3-17(18)23-19(24)22-16-9-11-21-12-10-16;;/h1-8,16,21H,9-13H2,(H,22,23);2*1H

Upstream product

• 7191-70-0 N-(4''-fluorobenzyl)-1,2-phenylenediamine 
• 95-54-5 1,2-diamino-benzene 
• 459-46-1 4-Fluorobenzyl bromide 
• 73733-81-0 ethyl 4-{[(2-aminophenyl)aminothioxomethyl]amino}-1-piperidinecarboxylate 
• 73733-70-7 ethyl 4-isothiocyanato-1-piperidinecarboxylate 
• 58859-46-4 ethyl 4-aminopiperidine-1-carboxylate 
• 352-11-4 1-chloromethyl-4-fluorobenzene 
• 73734-07-3 (1H-benzimidazol-2-yl)-(1-ethoxycarbonyl-piperidin-4-yl)amine 
• 84946-20-3 2-chloro-1-(4-fluorobenzyl)-1H-benzimidazole 
• 100460-87-5 1-<(4-fluorophenyl)methyl>-benzimidazol-2(3H)-one 
• 615-16-7 1H-benzimidazol-2-ol 
• 4857-06-1 2-chloro-1H-benzoimidazole 
• 84501-68-8 ethyl 4-[[1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl]amino]-1-piperidinecarboxylate 

Downstream Products

• 75971-08-3 α-(2-butoxyphenoxymethyl)-4-[1-(4-fluorophenylmethyl)-1H-benzimidazol-2-ylamino]-1-piperidineethanol 
• 68844-77-9 astemizole 
• 98088-84-7 1-(4-fluorobenzyl)-N-(1-phenethylpiperidin-4-yl)-1H-benzo[d]imidazol-2-amine 

Relevant articles and documents

Astemizole analogues with reduced hERG inhibition as potent antimalarial compounds

Astemizole is a H1-antagonist endowed with antimalarial activity, but has hERG liabilities. Systematic structural modifications of astemizole led to the discovery of analogues that display very potent activity as inhibitors of the growth of the Plasmodium parasite, but show a decreased hERG inhibition, when compared to astemizole. These compounds can be used as starting point for the development of a new class of antimalarials.

A short synthesis of astemizole

The synthesis of astemizole 6, a potent H1-antihistaminic agent, was achieved in 20% overall yield. Compound 6 was obtained in high purity and on a multigram scale starting from 2-hydroxybenzimidazole.

New Antihistaminic N-Heterocyclic 4-Piperidinamines. 2. Synthesis and Antihistaminic Activity of 1--N-(4-piperidinyl)-1H-benzimidazol-2-amines

The synthesis of a series of 1--N-(4-piperidinyl)-1H-benzimidazol-2-amines and the preliminary evaluation of their in vivo antihistamine activity are described.The title compounds were obtained starting from either 1, 4, 10, or 55 by different synthetic methods.Substitution on the phenyl nucleus of the benzimidazole ring (84-87) was achieved by two different approaches.The in vivo antihistamine activity was evaluated by the compound 48/80 induced lethality test in rats and the antihistamine-induced lethality test in guinea pigs after oral and/o r subcutaneous administration.The duration of action was studied in the guinea pig for three compounds (4, 51, and 55).Compound 51, "astemizole", was also studied in histamine- and serotonin-induced cutaneous reaction and for mydriatic activity in the rat and tested for peripheral and central effects not related to histamine antagonism in a variety of systems.Astemizole has been selected for clinical investigation.